Liang Yuanjing
School of Pharmaceutical Science and Technology, Tianjin University, 300072, Tianjin, PR China.
Clin Res Hepatol Gastroenterol. 2024 Oct;48(8):102434. doi: 10.1016/j.clinre.2024.102434. Epub 2024 Jul 29.
Liver cancer is one of the most common and devastating causes of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers and represents a significant global health issue. There is currently no effective systemic treatment for patients with advanced liver cancer. One study suggests that sorafenib may be effective against hepatocellular carcinoma. Sorafenib can significantly extend the median survival time of patients, but only by 3-5 months. Furthermore, it is linked to severe adverse side effects and frequently leads to drug resistance. In this review, we offer a critical analysis of the factors contributing to sorafenib resistance in HCC.
肝癌是全球癌症相关死亡最常见且最具毁灭性的原因之一。肝细胞癌（HCC）约占原发性肝癌的90%，是一个重大的全球健康问题。目前，晚期肝癌患者尚无有效的全身治疗方法。一项研究表明，索拉非尼可能对肝细胞癌有效。索拉非尼可显著延长患者的中位生存时间，但仅延长3至5个月。此外，它还与严重的不良反应有关，并经常导致耐药性。在本综述中，我们对导致HCC中索拉非尼耐药的因素进行了批判性分析。
